Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AgelessRx
• Treatments: Naltrexone; Niacinamide

Criteria

Inclusion Criteria:

• Any ethnicity

• Adequate cognitive function to be able to give informed consent

• Technologically competent to complete web forms and perform video calls with the PI

• Positive PCR test (polymerase chain reaction) result for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) 1-4 months before enrollment

• A fatigue score above 9 in the Chalder Fatigue scale upon enrollment

• Willing to fill out regular questionnaires

• Willing to use LDN and NAD patches

Exclusion Criteria:

• Clinically significant kidney, heart, Hepatic impairment as determined by clinical judgement

• Taking opioid analgesics, or undergoing treatment for opioid addiction

• Opioid dependence or withdrawal syndrome

• Known sensitivity to naltrexone

• Suspected or confirmed pregnancy or breastfeeding

• Known issues with using iontophoresis patches

• Active cancers

• Enrolled in another trial

• Current users of LDN or NAD+